Back to top
more

Atara Biotherapeutics (ATRA)

(Delayed Data from NSDQ)

$11.32 USD

11.32
14,045

-0.23 (-1.99%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $11.33 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in the Cards for Puma (PBYI) This Earnings Season?

by Zacks Equity Research

Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.

    Zacks Equity Research

    Is a Beat in Store for Adverum (ADVM) This Earnings Season?

    by Zacks Equity Research

    Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.

      Zacks Equity Research

      Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?

      by Zacks Equity Research

      On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.

        Zacks Equity Research

        What's in the Cards for Merrimack (MACK) in Q4 Earnings?

        by Zacks Equity Research

        Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.

          Zacks Equity Research

          What's in Store for Endocyte (ECYT) This Earnings Season?

          by Zacks Equity Research

          Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.

            Zacks Equity Research

            What's in the Cards for Ionis (IONS) This Earnings Season?

            by Zacks Equity Research

            Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

              Zacks Equity Research

              Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

              by Zacks Equity Research

              In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.

                Zacks Equity Research

                Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?

                by Zacks Equity Research

                ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.

                  Sweta Killa headshot

                  5 Best-Performing Stocks of the Top ETF of January

                  by Sweta Killa

                  Inside the top performing stocks of the top biotech ETF of January.

                    Zacks Equity Research

                    Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics

                    by Zacks Equity Research

                    Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics

                      Zacks Equity Research

                      3 Stocks in Focus on New Analyst Coverage

                      by Zacks Equity Research

                      Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.